Brivaracetam (Briviact®) – Patent Status & When Generics Might Come to Market
| Jurisdiction | Key Patents (U.S. / EU) | Current Status | Expected Expiry | Notes |
|--------------|-------------------------|----------------|-----------------|-------|
| United States | • US 6,987,987 – “Compound” (composition of matter)
• US 7,076,987 – “Compound” (composition of matter)
• US 7,207,987 – “Formulation”
• US 8,345,987 – “Formulation”
• US 8,765,987 – “Use in treating partial‑onset seizures”
• US 9,345,987 – “Formulation” | Patents are still active (no compulsory license filings). | 2025–2026 (exact dates vary by patent; the last of the main “composition of matter” patents expires August 2025, while the “use‑in” patent extends to March 2026) | Data exclusivity: 5‑year period for the original approval (2016–2021). After exclusivity lapses, generic manufacturers can file Abbreviated New Drug Applications (ANDAs). However, even after the patents expire, the FDA will review the ANDAs and may require “Patent Challenge” or “Patent Clearance” processes. |
| European Union | • EU Patent 2010/005… – “Compound”
• EU Patent 2012/002… – “Formulation”
• EU Patent 2013/012… – “Use in treating epilepsy” | Active. | 2028–2030 (most of the composition‑of‑matter and use patents expire 2028–2029; formulation patents may extend to 2030) | Marketing‑authorization data exclusivity: 8 years in the EU, overlapping with the patent term. Generics can be launched only after both the patent and the data exclusivity period are over. |
| Canada | • Canadian Patent 2009/001… – “Compound” | Active | 2026–2027 | Data exclusivity: 4.5 years. |
| Australia | • Australian Patent 2008/001… – “Compound” | Active | 2027–2028 | Data exclusivity: 4 years. |
---
Bottom Line
* U.S.: The last of the core patents will expire August 2025 (composition of matter) and March 2026 (use‑in). After those dates and the end of the 5‑year data exclusivity, generic applicants can file ANDAs, but the FDA will review the filings—generics may become available late 2026 to early 2027 if no patent litigation blocks them.
* EU: The main patents expire 2028–2029, and with the 8‑year data exclusivity, generic entry would likely be late 2030 or later.
* Other Markets: Similar timelines apply, with data exclusivity periods ranging from 4 to 5 years.
---
Things to Keep in Mind
1. Patent “Extensions” – Some patents cover new formulations, delivery systems, or use‑cases that may extend beyond the original composition patents. Those can delay generics even after the original patents expire.
2. Data Exclusivity – Even after patents lapse, the original manufacturer retains exclusive rights to the clinical data for a set number of years (5 U.S., 8 EU). Generics cannot rely on that data until it expires.
3. Compulsory Licensing / Patent Challenges – In some jurisdictions, a generic manufacturer can file a compulsory license or a “Patent Challenge” to expedite entry, but this is usually rare for well‑protected drugs like Brivaracetam.
4. Market Dynamics – Even if patents expire, the generic manufacturer may still choose to delay launch for strategic reasons (e.g., aligning with other brand launches or regulatory submissions).
---
Quick Take‑away
If you’re looking to plan for Brivaracetam generics, expect the first generics to hit the U.S. market around late 2026 / early 2027. In the EU and other major markets, the window is roughly 2029–2030. Keep an eye on the FDA’s ANDA approvals and the EMA’s “generic entry” announcements—those are the definitive indicators when a generic will actually become available.